Lumasiran + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Calcium Oxalate Kidney Stone Disease
Conditions
Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels
Trial Timeline
Jan 27, 2022 → Nov 1, 2022
NCT ID
NCT05161936About Lumasiran + Placebo
Lumasiran + Placebo is a phase 2 stage product being developed by Alnylam Pharmaceuticals for Recurrent Calcium Oxalate Kidney Stone Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05161936. Target conditions include Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Calcium Oxalate Kidney Stone Disease were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05161936 | Phase 2 | Terminated |
| NCT02706886 | Phase 1/2 | Completed |
Competing Products
20 competing products in Recurrent Calcium Oxalate Kidney Stone Disease